A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
AgeUp to 17
SponsorNovadip Biosciences

About this trial

The purpose of this study is to assess the efficacy and safety of NVD003 in pediatric participants with unilateral Congenital Pseudarthrosis of the Tibia (CPT) compared with iliac crest bone graft (ICBG) at 12 months post graft surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participant's parent(s)/legal guardian(s) have provided written informed consent (and assent has been provided by the participant, depending on age) for the study.

Participant is of any sex, ≤17 years of age.

Participant has been diagnosed with CPT (with or without NF1).

Participant has a non-healing Paley type 3 or 4 diaphyseal fracture.4

Disqualifiers

Participant has bilateral CPT.

Participant has evidence of plexiform neurofibroma of any size or nodular fibroma ≥1.2 inches/3 cm on the ipsilateral leg.

Participant has a clinically significant infection at the fracture site or systemic infection.

Participant's CPT fracture involves the metaphysis (i.e., not limited to the diaphysis).

Trial design

Design model

Parallel

Treatments tested in this trial

  • NVD003

    Biological/Vaccine

    Bone correction and grafting surgery

  • Iliac Crest Bone Graft

    Procedure/Surgery

    Either a single-stage Grafting Surgery with internal fixation and cross-union or the 2-stage "induced membrane" Grafting Surgery approach, depending on the surgeon's own standard of care.

Treatment groups

12 Participants
are divided into 2 treatment groups
Group A: Experimental ArmExperimental treatment 1 intervention
Group B: Standard of Care ArmActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

To assess the efficacy of NVD003 for the surgical treatment of CPT in pediatric participants

Overall healing at 12 months, defined as a binary (yes/no) outcome derived from the following 3 outcomes: * Radiographic healing, defined as a score ≥13 on the modified Radiological Union Scale for Tibia (mRUST) scale (range 1 to 16) assessed by independent central readers (ICRs) * Clinical healing measured by the absence of pain with weight-bearing, based on clinician's assessment * No use of secondary interventions to promote or accelerate bone healing All 3 criteria must be met for a "yes" on overall healing for this endpoint to be achieved.

Time frame
At 12 months post GS

Secondary outcomes

1

Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - radiographic healing

Radiographic healing, defined as a score ≥13 on the modified Radiological Union Scale for Tibia (mRUST) scale (range 1 to 16) assessed by independent central readers (ICRs)

Time frame
12 months after grafting surgery
2

Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - clinical healing

Clinical healing measured by the absence of pain with weight-bearing, based on clinician's assessment

Time frame
12 months after grafting surgery
3

Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - No use of secondary intervention

No use of secondary interventions to promote or accelerate bone healing

Time frame
12 months after grafting surgery
4

Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Adverse events

Number and severity of adverse events (AEs) related to NVD003

Time frame
12 months after grafting surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.